Baker Bros. Advisors ABCL Position
Active5-Fund ConvergenceBaker Bros. Advisors held their position in AbCellera Biologics Inc. (ABCL) in Q4 2025, holding $94.1M worth of shares across 27,525,640 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
ABCL is a convergence signal: 5 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for ABCL635 in 320 days (Feb 28, 2027), making the timing of Baker Bros.'s position particularly relevant.
Short interest stands at 21.5% of float with 14.3 days to cover, indicating significant bearish positioning against Baker Bros.'s long thesis.
About AbCellera Biologics Inc.
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Full company profile →Short Interest
21.5%
14.3 days to cover
Baker Bros. Advisors ABCL Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Held | 27,525,640 | — | $94.1M |
| Q3 2025 | Held | 27,525,640 | — | $138.5M |
| Q2 2025 | Held | 27,525,640 | — | $94.4M |
| Q1 2025 | Held | 27,525,640 | — | $61.4M |
| Q4 2024 | Held | 27,525,640 | — | $80.7M |
| Q3 2024 | Held | 27,525,640 | — | $71.6M |
| Q2 2024 | Held | 27,525,640 | — | $81.5M |
| Q1 2024 | Increased | 27,525,640 | +4,615,887 | $124.7M |
| Q4 2023 | Increased | 22,909,753 | +2,146,430 | $130.8M |
| Q3 2023 | Increased | 20,763,323 | +4,313,143 | $95.5M |
| Q2 2023 | Increased | 16,450,180 | +6,000,000 | $106.3M |
| Q1 2023 | New | 10,450,180 | +10,450,180 | $78.8M |
Frequently Asked Questions
Does Baker Bros. Advisors own ABCL?
Yes. As of Q4 2025, Baker Bros. Advisors holds 27,525,640 shares of AbCellera Biologics Inc. (ABCL) valued at $94.1M. This data comes from their SEC 13F filing.
How many hedge funds own ABCL?
5 specialist biotech hedge funds currently hold ABCL, including OrbiMed Advisors, Casdin Capital, Tang Capital Management and 1 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Baker Bros. Advisors first buy ABCL?
Baker Bros. Advisors's position in ABCL was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Baker Bros. Advisors's ABCL position increasing or decreasing?
Baker Bros. Advisors held their ABCL position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ABCLCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Baker Bros. AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →